Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
AVN-211
Другие языки:

    AVN-211

    Подписчиков: 0, рейтинг: 0
    AVN-211
    AVN-211 Structure.svg
    Clinical data
    Other names CD-008-0173
    Identifiers
    • 5,7-dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine
    CAS Number
    ChemSpider
    ChEMBL
    Chemical and physical data
    Formula C15H15N3O2S2
    Molar mass 333.42 g·mol−1
    3D model (JSmol)
    • Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C
    • InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3
    • Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N

    AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia. In early 2011, it successfully completed phase IIa clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase IIb clinical trials for schizophrenia began. Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.

    See also

    External links



    Новое сообщение